Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease.
OBJECTIVE
To evaluate the ability of once daily reduced dose clarithromycin to prevent disseminated Mycobacterium avium complex (dMAC) infection in patients with advanced HIV disease.


METHODS
Non-randomized, retrospective study.


METHODS
Outpatient clinic of an urban university-affiliated municipal hospital.


METHODS
A group of 192 HIV-infected patients with a CD4 count < 100 x 10(6) cells/l who were followed for at least 90 days during a 6-year period (1991-1996) before the use of protease inhibitors.


METHODS
Clarithromycin 500 mg orally once daily (n = 84), rifabutin 300 mg orally once daily (n = 47) or no prophylaxis (n = 61).


METHODS
Positive blood culture for M. avium complex (MAC), time to development of dMAC, and time to death.


RESULTS
When compared with no prophylaxis or rifabutin, the incidence of dMAC and time to development of dMAC were improved among those patients receiving clarithromycin (P < 0.001). Prolonged survival was associated with both clarithromycin and rifabutin use when compared with no prophylaxis (P < 0.002). In patients who failed prophylaxis, resistance to clarithromycin and rifabutin was observed.


CONCLUSIONS
In the era prior to protease inhibitor use, once daily clarithromycin at a dose of 500 mg was associated with a reduction in the incidence of dMAC, appeared to be superior to rifabutin, and was associated with prolonged survival in patients with advanced HIV disease.
Hewitt
R G
RG
Department of Medicine, State University of New York at Buffalo, USA.
Papandonatos
G D
GD
Shelton
M J
MJ
Hsiao
C B
CB
Harmon
B J
BJ
Kaczmarek
S R
SR
Amsterdam
D
D
D017088:AIDS-Related Opportunistic Infections / Q000401:mortality / Q000517:prevention & control*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D000904:Antibiotics, Antitubercular / Q000494:pharmacology / Q000627:therapeutic use; D001769:Blood / Q000382:microbiology; D017291:Clarithromycin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D015269:Mycobacterium avium Complex / Q000187:drug effects; D015270:Mycobacterium avium-intracellulare Infection / Q000517:prevention & control*; D012189:Retrospective Studies; D017828:Rifabutin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D017828:Rifabutin; D017291:Clarithromycin